Clinical Trial Update: An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Open-label Phase 1 study of a peptide vaccine in patients with stage IIb/IIIa non-small cell lung cancer; the trial sponsored by Epimmune is reported as complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Epimmune Peptide Vaccine (peptide vaccine)

Snippet

Sponsor: Epimmune | Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasm | Phase 1 | Status: COMPLETED